Vijaya Diagnost. Q2 FY26 Earnings Analysis

- Vijaya Diagnostic targets consistent revenue growth of 15%+ annually, backed by about 13% volume growth. - Price increases contribute approximately 1.5% to 2% of the revenue growth. - Existing (old) centers are expected to continue growing test volumes by around 9%-10%. - New centers contribute the remaining volume growth, with rapid ramp-up seen in newly entered markets like East India and Bangalore. - The company aims to expand revenue in new geographies (e.g., East India) to Rs. 50-100 crore within 2-3 years through opening hubs and spokes. - Growth is driven by market share gains, increased patient footfalls, and expansion into new regions. - Test mix changes and addition of advanced radiology services also support revenue growth. - Management expects volume growth and footfall to remain strong, supported by brand strength and digital marketing initiatives.

- The company maintains a consistent revenue growth guidance of 15%+ annually, driven primarily by volume growth (~13%) and price increases (1.5%-2%). - Earnings growth is supported by test volume growth; older centers are expected to grow volumes by 9%-10%, with the balance from new centers. - EBITDA margins are guided to be around 38%-38.5% for the full year, factoring in operating drags from new hub additions (~1%-1.5% margin impact). - New hubs are ramping up well, with break-even achieved generally at about 33% capacity utilization within the first 2-3 quarters. - Price increases are possible but selectively applied; no broad price hikes planned for the current financial year beyond Q1. - PAT margins remain healthy, around 20.4%, supported by operational leverage and volume growth. - CAPEX guidance for FY26 is Rs. 150-155 crores for new centers, indicating ongoing growth investments.

- For FY26, guided overall CAPEX for new centers is around Rs. 150-155 crores. - Replacement CAPEX expected at 2%-3% of overall topline. - Five new hubs have been commissioned in the current quarter; five more hubs planned for the next two quarters. - Scouting for new locations across core and new geographies (including Bangalore, Kolkata, Pune) is ongoing. - Finalization of plans for hub additions in FY27 is still in progress; more clarity expected by the next call. - Strategic focus is on expanding B2C business via new hubs and spokes, rather than participating in PPP models.

- There is no specific mention of any current or planned fundraising through debt or equity in the provided transcript. - The company discussed capital expenditure guidance for FY26, mentioning Rs. 150-155 crores for new centers and 2%-3% of overall topline for replacement CAPEX, indicating internal funding plans. - No explicit commentary on new debt or equity issuance was given during the Q&A or management commentary. - The company appears focused on organic growth and expansion through adding hubs and spokes without discussing fresh fundraising at this time. - Cash position as of June 30, 2025, was strong at around Rs. 270 crores (net cash Rs. 220 crores), suggesting available internal liquidity to support growth. In summary, no current or future debt/equity fundraising plans were disclosed in the July 28, 2025 call transcript.

The transcript on page 17 of the Vijaya Diagnostic Center Limited earnings call does not explicitly mention "current" or "expected orderbook" or "pending orders." However, some relevant points related to capacity and expansion plans that might indirectly reflect the company's growth pipeline are: - The company has added several new hubs recently and plans to open more hubs—five hubs opened in the current quarter, with five more expected to open in the next two quarters. - Discussions about scouting locations for FY27 hub additions are ongoing, with clearer updates expected in the next earnings call. - CAPEX guidance for FY26 for new centers is around Rs. 150-155 crores, with replacement CAPEX around 2%-3% of total revenue. - New centers in markets like Pune, Kolkata, and Bangalore are ramping up well, indicating active capacity expansion. No direct mention of specific orderbook quantification or pending orders was provided.